Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
2018 · Theranostics · 103 citations
https://doi.org/10.7150/thno.23177
Y
Ya‐Bin Tang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
987
Citations
16
h-index
22
i10-index
Ya‐Bin Tang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & RNA modifications and cancer & Cancer-related gene regulation. The author has an h-index of 16, co-authored 48 publications.
ORCID: 0000-0003-1823-6663Papers by this author
worksThe KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia
2022 · iScience · 5 citations
https://doi.org/10.1016/j.isci.2022.103881
Therapeutic targeting de novo purine biosynthesis driven by β-catenin-dependent PPAT upregulation in hepatoblastoma
2025 · Cell Death and Disease · 4 citations
https://doi.org/10.1038/s41419-025-07502-6
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers
2024 · Acta Pharmacologica Sinica · 0 citations
https://doi.org/10.1038/s41401-024-01409-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat